Sanofi Ends Drug Program After Late-Stage Trial in Lung Cancer Fails
21 Dicembre 2023 - 8:25AM
Dow Jones News
By Adria Calatayud
Sanofi said it would end a clinical-development program for its
tusamitamab ravtansine drug candidate after a late-stage trial in
previously treated patients with nonsmall cell lung cancer didn't
meet its primary goal.
The French pharmaceutical company said the decision came after
an independent data monitoring committee found that tusamitamab
ravtansine as a monotherapy didn't meet its primary goal of
progression-free survival compared to docetaxel. The trial had dual
primary goals of progression-free survival and overall
survival.
While overall survival improved, the decision on the trial was
based on a lack of improvement on progression-free survival, Sanofi
said Thursday.
Tusamitamab ravtansine had a similar safety profile as
previously presented, the company said.
Sanofi said it will continue exploring the potential of
tusamitamab-based antibody drug conjugates and research on the
potential of certain molecules as biomarkers in several types of
cancer.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
December 21, 2023 02:10 ET (07:10 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Apr 2023 a Apr 2024
